Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Not Confirmed
Not Confirmed
26-27 September, 2024
Oligo Chemistry & Ther...Oligo Chemistry & Therapeutics 2024
Not Confirmed
Not Confirmed
27 September, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Industry Trade Show
Not Confirmed
26-27 September, 2024
Oligo Chemistry & Ther...Oligo Chemistry & Therapeutics 2024
Webinar
Not Confirmed
27 September, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
23 Apr 2024
// BIOPHARMADIVE
https://www.biopharmadive.com/news/eli-lilly-nexus-manufacturing-factory-acquire/713897/
16 Apr 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216877
18 Mar 2024
// BUSINESSWIRE
29 Aug 2023
// BUSINESSWIRE
28 Aug 2023
// BUSINESSWIRE
23 Aug 2023
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217535
Details:
Baclofen is a gamma-aminobutyric acid (GABA-ergic) agonist. It is indicated for treatment of patients with multiple sclerosis, cerebral palsy, spinal cord injuries, and other conditions that result in muscle spasms.
Lead Product(s): Baclofen
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Nexus Pharmaceuticals Launches Baclofen Injection, USP
Details : Baclofen is a gamma-aminobutyric acid (GABA-ergic) agonist. It is indicated for treatment of patients with multiple sclerosis, cerebral palsy, spinal cord injuries, and other conditions that result in muscle spasms.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 18, 2024
Details:
Potassium Chloride Injection is a sterile, nonpyrogenic, highly concentrated, ready-to-use, which is indicated in the treatment of potassium deficiency states when oral replacement is not feasible.
Lead Product(s): Potassium Chloride
Therapeutic Area: Nutrition and Weight Loss Brand Name: Potassium Chloride-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Lead Product(s) : Potassium Chloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nexus Pharmaceuticals Receives FDA Approval for Potassium Chloride for Injection Concentrate, USP
Details : Potassium Chloride Injection is a sterile, nonpyrogenic, highly concentrated, ready-to-use, which is indicated in the treatment of potassium deficiency states when oral replacement is not feasible.
Brand Name : Potassium Chloride-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 15, 2023
Details:
Emerphed (ephedrine sulfate) is a sympathomimetic amine, an agonist at alpha- and beta-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons.
Lead Product(s): Ephedrine Sulfate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Emerphed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Lead Product(s) : Ephedrine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nexus Pharmaceuticals, Inc. Receives FDA Approval for EMERPHED® (ephedrine sulfate injection) Pre...
Details : Emerphed (ephedrine sulfate) is a sympathomimetic amine, an agonist at alpha- and beta-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons.
Brand Name : Emerphed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2023
Details:
Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor. It is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome.
Lead Product(s): Tirofiban
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tirofiban Hydrochloride-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection
Details : Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor. It is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome.
Brand Name : Tirofiban Hydrochloride-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 09, 2023
Details:
Erythromycin Lactobionate for Injection, USP is indicated in treatment of infections caused by susceptible strains of designated organisms when oral administration is not possible or when severity of infection requires immediate high serum levels of erythromycin.
Lead Product(s): Erythromycin Lactobionate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Erythromycin Lactobionate-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Lead Product(s) : Erythromycin Lactobionate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nexus Pharmaceuticals Announces Launch of Erythromycin Lactobionate for Injection, USP
Details : Erythromycin Lactobionate for Injection, USP is indicated in treatment of infections caused by susceptible strains of designated organisms when oral administration is not possible or when severity of infection requires immediate high serum levels of eryt...
Brand Name : Erythromycin Lactobionate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 21, 2022
Details:
Erythromycin Lactobionate for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible.
Lead Product(s): Erythromycin Lactobionate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Erythromycin Lactobionate-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2022
Lead Product(s) : Erythromycin Lactobionate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nexus Pharmaceuticals Inc. Receives FDA Approval of Erythromycin
Details : Erythromycin Lactobionate for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible.
Brand Name : Erythromycin Lactobionate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 17, 2022
Details:
Ephedrine Sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
Lead Product(s): Ephedrine Sulfate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Emerphed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2021
Lead Product(s) : Ephedrine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nexus Pharmaceuticals Receives Patent for EMERPHED® Ready-To-Use Ephedrine Sulfate Injection
Details : Ephedrine Sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
Brand Name : Emerphed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 17, 2021
Details:
Nexus Pharmaceuticals has announced that it has received U.S. FDA approval for Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, 20mEq/100mL, 40mEq/100mL and 20mEq/50mL Single-Dose IV bags.
Lead Product(s): Potassium Chloride
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2021
Lead Product(s) : Potassium Chloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nexus Pharmaceuticals Receives FDA Approval for Potassium Chloride in Water for Injection
Details : Nexus Pharmaceuticals has announced that it has received U.S. FDA approval for Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, 20mEq/100mL, 40mEq/100mL and 20mEq/50mL Single-Dose IV bags.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 28, 2021
Details:
Nexus Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN.
Lead Product(s): Succinylcholine Chloride
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nexus Pharmaceuticals Receives FDA Approval for Succinylcholine Chloride Injection, USP
Details : Nexus Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 29, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?